U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07398664) titled 'H101 Plus TACE for r/m HNSCC' on Jan. 31.
Brief Summary: This study evaluates H101 combined with transarterial chemoembolization (TACE) to enhance local tumor killing and immune activation while minimizing toxicity in r/m HNSCC patients.
Study Start Date: Feb. 15
Study Type: INTERVENTIONAL
Condition:
Head and Neck Squamous Cell Carcinoma
Oncolytic Virus
TACE
Intervention:
DRUG: H101
H101 combined with transarterial chemoembolization (TACE) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (r/m HNSCC)
PROCEDURE: TACE
H101 combined with transarterial chemoembolization (TACE) for the treatment ...